Targeted drug LDK378 takes aim at rare ROS1-driven lung cancer

NCT ID NCT01964157

Completed Disease control Sponsor: Yonsei University Source: ClinicalTrials.gov ↗

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This phase 2 trial tests the experimental drug LDK378 in adults with advanced non-small cell lung cancer that has a specific genetic change called a ROS1 rearrangement. Participants must have already received at least one platinum-based chemotherapy and their cancer must have progressed. The study measures how many patients' tumors shrink or disappear and tracks side effects. LDK378 is taken daily as a pill in 28-day cycles.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental ALK/ROS1 inhibitor called LDK378
What this could lead to: If effective, LDK378 could offer a new targeted treatment option for people with a rare genetic form of lung cancer that has stopped responding to standard chemotherapy.
What could go wrong: This is a small, early-phase trial with only 32 participants, so results may not apply broadly. The drug may cause side effects or fail to shrink tumors in many patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER (NSCLC)

Contacts and locations

Show contact details

Locations

Yonsei Cancer Center at Yonsei University Medical Center

Seoul, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.